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Background
Without antiretroviral therapy (ART), approximately 20%
of HIV-1 vertically infected infants develop severe disease
manifestations before the age of 1 year [1] and surrogate
markers poorly predict infants at higher risk of rapid dis-
ease progression. Several small prospective and retrospec-
tive studies in developed countries have suggested that
ART initiated early in life could prevent this rapid clinical
and immunologic deterioration [2-6].
Because of the small number of HIV-infected infants
delivered in industrialized countries where mother to
child transmission prophylaxis is widely applied, a pro-
spective study of early versus delayed ART is currently not
feasible. Implementation of early ART has varied across
countries and over time since 1996 in Europe. The objec-
tive of this collaborative study was to compare the out-
come of infants who received ART early in life with the
outcome of those with deferred treatment.
Materials and methods
Children born between 01/09/96 and 31/12/2004 to
mothers with known HIV infection at birth, who received
neonatal prophylaxis, and diagnosed with HIV before age
3 months were eligible. The children who were identified
as HIV-infected at the same time or after being diagnosed
with AIDS, and children who develop AIDS before the age
of 3 months were excluded. Thirteen prospective and ret-
rospective cohorts from 11 European countries partici-
pated, enrolling a total of 210 eligible infants. Data
including general demographics and pregnancy data,
details of prophylaxis and ART in early life, CDC events
and death, immunological and virological measurements
since birth, were collected and pooled. The risk of AIDS/
death was estimated by Kaplan-Meier survival analysis,
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and compared between the groups of infant treated or not
treated before 3 months of age. Cox regression was used
to estimate hazard ratios.
Results
Among the 210 children, 21 developed AIDS and 3 died.
The exposure to treatment was heterogeneous among
cohorts. Overall ART and Highly active ART were initiated
in 59% and 48% of the infants before 3 months of age and
in 87% and 76% by one year, respectively.
Treatment was initiated before the age of 3 months in 124
infants. There was no significant difference in demo-
graphic, pregnancy and delivery characteristics between
the two groups. Moreover the proportion of infants with
early treatment did not vary significantly over time. As
shown in figure 1, we found that the risk of developing
AIDS/death at one year was 1.6% in infants treated before
the age of 3 months compared to 11.7% in infants who
started treatment later (p<0.001). At 5 years the risks were
4.6% and 21.5% respectively. Deferred treatment was
associated with a five-fold higher risk of AIDS has com-
pared with treatment before 3 months of age (crude haz-
ard ratio = 5.0; 95% CI: 2.0-12.6). Adjustment for
ethnicity, birth weight, breast feeding, number and class
of neonatal prophylaxis, number and class of drug in first
treatment did not substantially affect the hazard ratio.
Conclusion
The preliminary results of this retrospective collaborative
study suggest a significant association between ART
started before the age of 3 months and a lower subsequent
incidence of AIDS/death in infancy.
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